Venetoclax

ISAL session highlights: targeting CD123, CD47 & TP53 in AML 2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
The promise of CD123-directed immunotherapy in AML and agents of interest 1:40
The promise of CD123-directed immunotherapy in AML and agents of interest
Farhad Ravandi • 21 Mar 2023
Novel combinations being explored in AML using an HMA-venetoclax backbone 4:38
Novel combinations being explored in AML using an HMA-venetoclax backbone
Marina Konopleva • 20 Mar 2023
The importance of targeting TP53 in AML and agents being explored 1:38
The importance of targeting TP53 in AML and agents being explored
David Sallman • 20 Mar 2023
ENHANCE-2 and ENHANCE-3: exploring magrolimab combinations in AML 1:35
ENHANCE-2 and ENHANCE-3: exploring magrolimab combinations in AML
David Sallman • 20 Mar 2023
Infectious complications & outcomes of patients with AML receiving treatment with HMAs ± venetoclax 2:21
Infectious complications & outcomes of patients with AML receiving treatment with HMAs ± venetoclax
Livio Pagano • 16 Mar 2023
CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS 1:12
CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS
Jayastu Senapati • 11 Dec 2022
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL 1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL 1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML 1:23
The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML
Eunice Wang • 12 Dec 2022
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML 2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022
Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens 3:42
Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens
Michael Wang • 21 Dec 2022
Key updates in MDS from ASH on magrolimab, sabatolimab, venetoclax & tamibarotene 2:00
Key updates in MDS from ASH on magrolimab, sabatolimab, venetoclax & tamibarotene
David Sallman • 11 Dec 2022
The importance of molecular characterization and precision medicine in AML 2:25
The importance of molecular characterization and precision medicine in AML
Claudio Cerchione • 12 Dec 2022
Azacitidine and venetoclax +/- gemtuzumab ozogamicin in pediatric patients with R/R acute leukemias 1:23
Azacitidine and venetoclax +/- gemtuzumab ozogamicin in pediatric patients with R/R acute leukemias
Sarah Tasian • 10 Dec 2022
Genomic factors influencing patient response to venetoclax-based regimens: analysis from CLL13/GAIA 3:28
Genomic factors influencing patient response to venetoclax-based regimens: analysis from CLL13/GAIA
Barbara Eichhorst • 11 Dec 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals